Just some quick research I've done, I'll look to post more on my blog later tonight. In answer to the question of how much of the 70m+ revenue will be applied to ADO...
From the ADO announcement:Don Tartre, President and CEO of eBioscience, said: “We are pleased to work in partnership with the Anteo Diagnostics team to exploit an innovative technology to leverage our FlowCytomix™ bead-based immunoassay product line to even higher performance including greater sensitivity.
From this news story on the eBioscience deal with affy:In comparison, Witney said that eBioscience has 16 percent share of the $200 million North American flow cytometry market and an 11 percent share of the $450 million flow reagent market. Witney described eBioscience as a "solid number two player worldwide." In both North America and globally, the firm's main competitor is BD Pharmingen, a business unit of BD Biosciences.
Assuming the eBioscience product "FlowCytomix" is the revenue earned in the "cytometry market" referred to above:
16% of $200m = $32m -- which is almost half of their revenue coming from the product mentioned in the ADO announcement.
flowcytomix
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.36M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.1¢ | 2.0¢ | $21.31K | 1.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 5730857 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 724070 | 5 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| ADO (ASX) Chart |